DENVER, May 05, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization…


Previous articleSmall Pharma Inc. to Commence Trading on the TSX Venture Exchange on May 6, 2021
Next articleRed Light Holland Receives Patent Pending Status For ‘Find Your Dose’ Customization of Microdosing Kits Based on Biometric and Movement Data